For citations:
Kovalenko EI, Artamonova EV, Bolotina LV, Zhiliaeva LA, Ponomarenko DM, Karabina EV, Mukhametshina GZ, Khasanova AI, Ratner EY, Safarova AR, Manikhas AG, Popova NO, Evstigneeva IV, Vladimirova LY, Kramskaya LV, Karandeeva TV, Suslova IR, Romanchuk OV, Shikina VE, Povyshev AY, Osipov MA, Cherniakova EM, Dergunov AS, Volkonskiy MV, Chernov IS, Shumskaya IE, Fael MM, Garifullina VI, Gudkova IE. Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study. Meditsinskiy sovet = Medical Council. 2021;(20):36-46. (In Russ.) https://doi.org/10.21518/2079-701X-2021-20-36-46